Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search
ACR Convergence graphic

Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

Jason Liebowitz, MD, FACR  |  December 4, 2020

Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.

L. Manuela Marinescu, MD, Takes Reins as Chair of Affiliate Society Council

Gretchen Henkel  |  December 4, 2020

While an active member of her state rheumatology society, L. Manuela Marinescu, MD, saw the value of connecting with other regional groups to share information and advocacy strategies. On Nov. 16, she assumed the role of chair of the ACR’s Affiliate Society Council (ASC), where she will help facilitate those connections. Dr. Marinescu graduated with…

Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients

Michele B. Kaufman, PharmD, BCGP  |  December 4, 2020

The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.

Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2020

The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.

Riding Out the Pandemic: A Q&A with Norman Gaylis, MD

Kimberly Retzlaff  |  November 30, 2020

Some aspects of community practice are normalizing amid the ongoing COVID-19 pandemic, but the financial fallout and the need for increased safety precautions remain challenging.

Resetting Immune Tolerance to Prevent RA

Mary Beth Nierengarten  |  November 24, 2020

Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.

What Does the ‘New Normal’ Look Like? A Q&A with Jay Mehta, MD

Mary Choy, PharmD, BCGP, FASHP  |  November 24, 2020

With his clinic resuming in-person visits, Jay Mehta, MD, says his patients and staff have proved remarkably adaptable, embracing telemedicine during the early days of the pandemic and now facemasks during appointments.

Pulmonary Adverse Events with Low-Dose Methotrexate

Arthritis & Rheumatology  |  November 24, 2020

In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.

Tofacitinib Promising for Adults with AS

Michele B. Kaufman, PharmD, BCGP  |  November 24, 2020

According to a recent phase 3 study, tofacitinib may be a safe and effective treatment for adult patients with ankylosing spondylitis (AS).

2020 Pediatric Rheumatology Research in Review

Carina Stanton  |  November 24, 2020

ACR CONVERGENCE 2020—This has been a busy year for research publications covering a number of pediatric rheumatic diseases, including the emerging multi-system inflammatory syndrome (MIS-C) associated with SARS CoV-2. Despite the many challenges brought about by the COVID-19 pandemic, a healthy collection of publications covering a wide range of pediatric rheumatology research topics were published…

  • « Previous Page
  • 1
  • …
  • 169
  • 170
  • 171
  • 172
  • 173
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences